Anthony D. Sung, MD, Primary Investigator
Fellowship, Hematology Oncology, Duke University School of Medicine, 2011 - 2014
Residency, Osler Medical Housestaff Training Program, Johns Hopkins University School of Medicine, 2008 - 2011
M.D., Harvard University , 2008
Research in the Sung lab focuses on strategies to reduce complications of HCT and ranges from preclinical studies using murine models of HCT to Phase 1 and Phase 2 clinical trials.
Lab Research Analyst, Senior
Lab Research Analyst I
Research Program Leader, Sr
Research Program Leader
Clinical Research Coordinator, Tier 2
Clinical Research Coordinator, Tier 1
Clinical Research Specialist, Sr
Research Technician II
I am dedicated to the treatment of hematologic malignancies through cellular therapies such as hematopoietic stem cell transplantation (HCT). My research focuses on strategies to reduce complications of HCT and ranges from preclinical studies using murine models of HCT to Phase 1 and Phase 2 clinical trials. Areas of interest include the role of the microbiota (the trillions of bacteria living in and on our bodies), nutrition, and exercise in modulating HCT outcomes such as graft-versus-host disease (GVHD) and infections. In addition to advancing new pharmacological and cellular immunotherapies in support of these goals, we also are developing mobile health technologies (mHealth) to monitor patients at home, both as part of our innovative home transplant program as well as to improve follow up care of all our patients when they return home after transplant.